H3 K27M clinical trials at UCSF
1 research study open to eligible people
H3 K27M is a genetic change found in some brain tumors. UCSF is researching new ways to treat these tumors after radiation therapy. One clinical trial is studying the effects of the drug ONC201 on patients with this mutation.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
open to all eligible people
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
San Francisco, California and other locations
Our lead scientists for H3 K27M research studies include Nicholas Butowski, MD.
Last updated: